Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in C ...
Hutchmed (China) Limited 14 January 2025 Press Release HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for...
Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd t ...
Hutchmed (China) Limited 02 January 2025 Press Release HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS®...
Hutchmed (China) Limited 02 January 2025 Overseas Regulatory Announcement - Disposal Transaction HUTCHMED (China) Limited ("HUTCHMED...
Hutchmed (China) Limited 02 January 2025 HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - HUTCHMED continues to...
Hutchmed (China) Limited 31 December 2024 Appointment of Cavendish as Joint Corporate Broker in London Hong Kong, Shanghai & Florham...
Hutchmed (China) Limited 30 December 2024 Blocklisting Six Monthly Return Hong Kong, Shanghai & Florham Park, NJ - Monday, December 30...
Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pha ...
Hutchmed (China) Limited 13 December 2024 Press Release HUTCHMED to Receive Milestone Payment from Takeda following First European...
Hutchmed (China) Limited 12 December 2024 Press Release HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and...
Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endomet ...
Hutchmed (China) Limited 03 December 2024 Press Release HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE®...
Hutchmed (China) Limited 29 November 2024 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Friday, November 29, 2024:...
Hutchmed (China) Limited 28 November 2024 Press Release HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads